Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
IBI-130
i
Other names:
IBI-130, IBI130
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Innovent Biologics
Drug class:
TROP-2-targeted antibody-drug conjugate
Related drugs:
‹
sacituzumab govitecan-hziy (17)
DS-1062a (11)
DM001 (6)
LCB84 (4)
BCG033 (3)
MK-2870 (3)
BAT8003 (1)
BAT8008 (1)
BL-M02D1 (1)
ESG401 (1)
OBI-992 (1)
YH012 (1)
hIMB1636-MMAE (1)
FZ-AD004 (0)
JS108 (0)
MHB036C (0)
SHR-A1921 (0)
anti TROP-2 antibody therapeutic (0)
sacituzumab govitecan-hziy (17)
DS-1062a (11)
DM001 (6)
LCB84 (4)
BCG033 (3)
MK-2870 (3)
BAT8003 (1)
BAT8008 (1)
BL-M02D1 (1)
ESG401 (1)
OBI-992 (1)
YH012 (1)
hIMB1636-MMAE (1)
FZ-AD004 (0)
JS108 (0)
MHB036C (0)
SHR-A1921 (0)
anti TROP-2 antibody therapeutic (0)
›
Associations
News
Trials
Filter by
Latest
12ms
A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=182, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
12 months ago
Enrollment open
|
IBI-130
over1year
A Phase 1/2 Clinical Study to Evaluate the Safety and Tolerability of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=182, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
over 1 year ago
New P1/2 trial • Metastases
|
IBI-130
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login